These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8630071)

  • 1. A modular approach to HIV-1 proteinase inhibitor design.
    Uhlíková T; Konvalinka J; Pichová I; Soucek M; Kräusslich HG; Vondrásek J
    Biochem Biophys Res Commun; 1996 May; 222(1):38-43. PubMed ID: 8630071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design of symmetry-based, peptidomimetic inhibitors of human immunodeficiency virus protease.
    Kempf DJ
    Methods Enzymol; 1994; 241():334-54. PubMed ID: 7854187
    [No Abstract]   [Full Text] [Related]  

  • 3. Crystal structure of a tethered dimer of HIV-1 proteinase complexed with an inhibitor.
    Bhat TN; Baldwin ET; Liu B; Cheng YS; Erickson JW
    Nat Struct Biol; 1994 Aug; 1(8):552-6. PubMed ID: 7664084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design of tight-binding human immunodeficiency virus type 1 protease inhibitors.
    Vacca JP
    Methods Enzymol; 1994; 241():311-34. PubMed ID: 7854186
    [No Abstract]   [Full Text] [Related]  

  • 5. Dimer disruption and monomer sequestration by alkyl tripeptides are successful strategies for inhibiting wild-type and multidrug-resistant mutated HIV-1 proteases.
    Bannwarth L; Rose T; Dufau L; Vanderesse R; Dumond J; Jamart-Grégoire B; Pannecouque C; De Clercq E; Reboud-Ravaux M
    Biochemistry; 2009 Jan; 48(2):379-87. PubMed ID: 19105629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates.
    Song M; Rajesh S; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2001 Sep; 11(18):2465-8. PubMed ID: 11549448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyquinones are competitive non-peptide inhibitors of HIV-1 proteinase.
    Brinkworth RI; Fairlie DP
    Biochim Biophys Acta; 1995 Nov; 1253(1):5-8. PubMed ID: 7492599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
    Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
    J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide aldehydes as inhibitors of HIV protease.
    Sarubbi E; Seneci PF; Angelastro MR; Peet NP; Denaro M; Islam K
    FEBS Lett; 1993 Mar; 319(3):253-6. PubMed ID: 8458418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutron crystallography used to identify targets to improve HIV-1 protease inhibitor.
    Hill R
    Future Med Chem; 2013 Oct; 5(15):1705. PubMed ID: 24144407
    [No Abstract]   [Full Text] [Related]  

  • 11. Pentacycloundecane derived hydroxy acid peptides: a new class of irreversible non-scissile ether bridged type isoster as potential HIV-1 wild type C-SA protease inhibitors.
    Karpoormath R; Sayed Y; Govender P; Govender T; Kruger HG; Soliman MES; Maguire GEM
    Bioorg Chem; 2012 Feb; 40(1):19-29. PubMed ID: 21982718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic.
    Kiso Y; Matsumoto H; Mizumoto S; Kimura T; Fujiwara Y; Akaji K
    Biopolymers; 1999; 51(1):59-68. PubMed ID: 10380353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
    Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
    J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching between allosteric and dimerization inhibition of HIV-1 protease.
    Bowman MJ; Byrne S; Chmielewski J
    Chem Biol; 2005 Apr; 12(4):439-44. PubMed ID: 15850980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enamino-oxindole HIV protease inhibitors.
    Eissenstat M; Guerassina T; Gulnik S; Afonina E; Silva AM; Ludtke D; Yokoe H; Yu B; Erickson J
    Bioorg Med Chem Lett; 2012 Aug; 22(15):5078-83. PubMed ID: 22749283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental and 'in silico' analysis of the effect of pH on HIV-1 protease inhibitor affinity: implications for the charge state of the protein ionogenic groups.
    Domínguez JL; Gossas T; Carmen Villaverde M; Helena Danielson U; Sussman F
    Bioorg Med Chem; 2012 Aug; 20(15):4838-47. PubMed ID: 22743085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 RT enhances the activity of a tethered dimer of HIV-1 proteinase.
    Goobar-Larsson L; Larsson PT; Debouck C; Towler EM
    Biochem Biophys Res Commun; 1996 Mar; 220(1):203-7. PubMed ID: 8602845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Triterpenes as potential dimerization inhibitors of HIV-1 protease.
    Quéré L; Wenger T; Schramm HJ
    Biochem Biophys Res Commun; 1996 Oct; 227(2):484-8. PubMed ID: 8967903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.